Prostate cancer (PCa) represents the second most prevalent cancer in men and the fifth cause of cancer-related mortality worldwide (1). Bone secondary tumor localizations are the most frequent expression of advanced PCa, representing the cause of morbidity and mortality and determining a poor prognosis. Several studies have been provided concerning the clinical outcomes of Radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) (2,3). Moreover, patients with mCRPC could suffer from hematologic comorbidities. Notably, to our knowledge, there are no studies involving the use of Radium-223 in patients with mCRPC and preexisting hematological conditions, such as polycythemia vera (PV), a chronic myeloproliferative disorder. Thus, studies that could support clinicians to predict eventual adverse effects (AEs) in these cases are warranted.
Ethics
Informed Consent: Informed consent was obtained from the patient.
Peer-review: Externally peer-reviewed.
Authorship Contributions
Surgical and Medical Practices: C.A., J.L., M.S.F., Concept: G.V., V.F., Design: G.V., V.F., M.P., Data Collection or Processing: V.F., C.A., Analysis or Interpretation: G.V., V.F., M.P., Literature Search: C.A., J.L., M.S.F., Writing: C.A., M.P., J.L.
Conflict of Interest: No conflict of interest was declared by the authors.
Financial Disclosure: The authors declared that this study received no financial support.
